Kalvista Pharmaceuticals, INC Form 4 insider transactions

CEO Benjamin Palleiko reports the vesting and sale of KalVista Pharmaceuticals stock to cover tax obligations.

Venrock Healthcare Capital Partners III, L.P. reports purchasing additional shares of KalVista Pharmaceuticals, Inc. common stock, increasing its beneficial ownership.

Venrock Healthcare Capital Partners III, L.P. and related entities have increased their holdings in KalVista Pharmaceuticals, Inc. through a series of open market purchases.

Venrock Healthcare Capital Partners III, L.P. and related entities have increased their holdings in KalVista Pharmaceuticals, Inc. through a series of open market purchases.

KalVista Pharmaceuticals CEO, Benjamin L. Palleiko, sold shares to cover tax obligations following the vesting of restricted stock units.

KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, sold 2,187 shares to cover tax obligations related to the vesting of restricted stock units.

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, sold 1,963 shares to cover tax obligations following the vesting of restricted stock units.

KalVista Pharmaceuticals director, Laurence Reid, acquired 17,000 stock options with a strike price of $10.07, vesting over 36 months.

KalVista Pharmaceuticals CEO Benjamin Palleiko acquired shares through vesting of restricted stock units and performance stock units, and sold a portion to cover tax obligations.

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, sold 7,192 shares to cover tax obligations following the vesting of restricted stock units and performance stock units.

KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, executed stock transactions involving the vesting of restricted stock units and performance stock units, followed by a sale of shares to cover tax obligations.

William Fairey, a director of KalVista Pharmaceuticals, acquired stock options for 10,000 shares on October 3, 2024.

Brian JG Pereira, a director of KalVista Pharmaceuticals, acquired stock options for 10,000 shares at an exercise price of $11.54 on October 3, 2024.

Director Nancy Stuart acquired stock options for 10,000 shares of KalVista Pharmaceuticals on October 3, 2024.

Director Patrick Treanor acquired 10,000 stock options in KalVista Pharmaceuticals on October 3, 2024.

Director Edward W Unkart acquired stock options for 10,000 shares of KalVista Pharmaceuticals, Inc. on October 3, 2024.

Brian Piekos, CFO of KalVista Pharmaceuticals, was granted stock options for 100,000 shares on September 9, 2024, according to a Form 4 filing.

CEO Benjamin Palleiko of KalVista Pharmaceuticals reports the acquisition of shares through RSU vesting and subsequent sale to cover tax obligations.

Paul K. Audhya, Chief Medical Officer of KalVista Pharmaceuticals, sold shares to cover tax withholding obligations related to vesting of restricted stock units.

Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, reports the acquisition and disposal of company stock, including sales to cover tax obligations related to vesting restricted stock units.

Paul K. Audhya, Chief Medical Officer of KalVista Pharmaceuticals, reports acquisition and disposal of common stock and derivative securities, including transactions to cover tax obligations.

CEO Benjamin Palleiko reports acquisition of shares through stock unit vesting and sales to cover tax obligations.

Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting of restricted stock units (RSUs) and performance stock units (PSUs).

CEO Benjamin Palleiko of KalVista Pharmaceuticals reports acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, received 50,000 restricted stock units on May 22, 2024, according to a Form 4 filing.

Paul K. Audhya, Chief Medical Officer of KalVista Pharmaceuticals, was granted 80,000 restricted stock units (RSUs) on May 22, 2024, according to a recent SEC Form 4 filing.

Edward P. Feener, Chief Scientific Officer of KalVista Pharmaceuticals, sold shares to cover tax withholding obligations related to vesting of restricted stock units and performance stock units.

Paul K. Audhya, Chief Medical Officer of KalVista Pharmaceuticals, reports the vesting and sale of shares to cover tax obligations.

CEO Benjamin Palleiko reports acquisition and disposal of KalVista Pharmaceuticals stock, including sales to cover tax obligations related to vesting of restricted stock units and performance stock units.

Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, sold shares to cover tax withholding obligations related to vesting of restricted stock units and performance stock units.